MCID: ATT013
MIFTS: 66

Attention Deficit-Hyperactivity Disorder

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Attention Deficit-Hyperactivity Disorder

MalaCards integrated aliases for Attention Deficit-Hyperactivity Disorder:

Name: Attention Deficit-Hyperactivity Disorder 54 51
Attention Deficit Hyperactivity Disorder 39 12 29 41 14 69
Adhd 39 12 51 3
Attention Deficit Disorder 12 52 69
Attention-Deficit/hyperactivity Disorder, Predominantly Inattentive Type 69
Attention Deficit-Hyperactivity Disorder, Susceptibility to 13
Attention Deficit Disorder with Hyperactivity 42
Attention-Deficit Hyperactivity Disorder 52
Hyperkinetic Disorder 12

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant


HPO:

32
attention deficit-hyperactivity disorder:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 143465
Disease Ontology 12 DOID:1094
ICD9CM 35 314.8
MeSH 42 D001289
NCIt 47 C35092
ICD10 33 F90 F90.0 F90.9

Summaries for Attention Deficit-Hyperactivity Disorder

MedlinePlus : 41 is it hard for your child to sit still? does your child act without thinking first? does your child start but not finish things? if so, your child may have attention deficit hyperactivity disorder (adhd). nearly everyone shows some of these behaviors at times, but adhd lasts more than 6 months and causes problems in school, at home and in social situations. adhd is more common in boys than girls. it affects 3-5 percent of all american children. the main features of adhd are inattention hyperactivity impulsivity no one knows exactly what causes adhd. it sometimes runs in families, so genetics may be a factor. there may also be environmental factors. a complete evaluation by a trained professional is the only way to know for sure if your child has adhd. treatment may include medicine to control symptoms, therapy, or both. structure at home and at school is important. parent training may also help. nih: national institute of mental health

MalaCards based summary : Attention Deficit-Hyperactivity Disorder, also known as attention deficit hyperactivity disorder, is related to pervasive developmental disorder and schizophrenia, and has symptoms including hyperactivity, attention deficit hyperactivity disorder and back pain. An important gene associated with Attention Deficit-Hyperactivity Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Circadian entrainment and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and thyroid, and related phenotypes are behavior/neurological and cardiovascular system

CDC : 3 Key Findings: A National Profile of Attention-Deficit Hyperactivity Disorder Diagnosis and Treatment Among US Children Aged 2 to 5 Years

NINDS : 51 Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral). Some of the warning signs of ADHD include failure to listen to instructions, inability to organize oneself and school work, fidgeting with hands and feet, talking too much, leaving projects, chores and homework unfinished, and having trouble paying attention to and responding to details. There are several types of ADHD: a predominantly inattentive subtype, a predominantly hyperactive-impulsive subtype, and a combined subtype. ADHD is usually diagnosed in childhood, although the condition can continue into the adult years.

Disease Ontology : 12 A specific developmental disorder that is characterized by co-existence of attentional problems and hyperactivity, with each behavior occurring infrequently alone\

Description from OMIM: 143465

Related Diseases for Attention Deficit-Hyperactivity Disorder

Diseases related to Attention Deficit-Hyperactivity Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
id Related Disease Score Top Affiliating Genes
1 pervasive developmental disorder 32.3 COMT DRD4 DRD5 MECP2 SLC6A2 SLC6A3
2 schizophrenia 32.2 COMT DRD3 DRD4 DRD5 SLC6A2 SLC6A3
3 personality disorder 32.2 COMT DRD3 DRD4 MECP2 SLC6A2 SLC6A3
4 heroin dependence 31.6 DRD3 DRD4 DRD5 SLC6A3 SLC6A4
5 antisocial personality disorder 31.5 DRD3 DRD4
6 dissociative disorder 31.4 DRD3 SLC6A4
7 attention deficit-hyperactivity disorder susceptibility, adhd4-related 12.3
8 attention deficit-hyperactivity disorder susceptibility, drd4-related 12.3
9 attention deficit-hyperactivity disorder susceptibility, drd5-related 12.3
10 language delay and adhd/cognitive impairment with or without cardiac arrhythmia 11.9
11 aarskog-scott syndrome 11.6
12 gilles de la tourette syndrome 11.2
13 contact dermatitis 11.2 DRD4 DRD5 SLC6A3 TPH2
14 pyromania 11.2 DRD3 DRD4 SLC6A3 SLC6A4
15 hemorrhagic cystitis 11.2 COMT DRD4 SLC6A2 SLC6A3 SLC6A4 TPH2
16 carotid stenosis 11.2 COMT DRD4 DRD5 SLC6A3 SLC6A4
17 hepatitis d 11.1 COMT DRD4 SLC6A2 SLC6A3 SLC6A4 TPH2
18 cecal benign neoplasm 11.1 COMT DRD3 DRD4 SLC6A3 SLC6A4 TPH2
19 tongue disease 11.1 COMT SLC6A3 SLC6A4
20 keratosis 11.1 COMT SLC6A2 SLC6A4 TPH2
21 pauci-immune glomerulonephritis with anca 11.1 COMT DRD3 DRD4 SLC6A4
22 aicardi-goutieres syndrome 2 11.1 COMT DRD3 DRD4 SLC6A3 SLC6A4 TPH2
23 osteogenesis imperfecta, type ix 11.1 ADRA2A COMT DRD4 DRD5 SLC6A3
24 colon mucinous adenocarcinoma 11.1 COMT DRD3 DRD4 DRD5 SLC6A3 SLC6A4
25 chronic conjunctivitis 11.1 COMT DRD3 DRD4 SLC6A3 SLC6A4
26 intrahepatic gall duct cancer 11.1 COMT SLC6A4 TPH2
27 partial motor epilepsy 11.1 COMT DRD4 SLC6A2 SLC6A4 TPH2
28 may-hegglin anomaly 11.1 COMT SLC6A2 SLC6A4 TPH2
29 bladder hepatoid adenocarcinoma 11.1 SLC6A2 SLC6A3 SLC6A4
30 epileptic encephalopathy, early infantile, 45 11.1 COMT DRD3 DRD4 SLC6A3 SLC6A4 TPH2
31 laryngeal adductor paralysis 11.1 DRD4 SLC6A4 TPH2
32 bone fracture 11.1 COMT DRD3 SLC6A3 SLC6A4 TPH2
33 acute female pelvic peritonitis 11.1 DRD3 SLC6A3 SLC6A4
34 perinatal necrotizing enterocolitis 11.1 COMT SLC6A3 SLC6A4
35 albinism, oculocutaneous, type v 11.1 COMT DRD3 DRD4 DRD5 SLC6A4
36 parkinson disease, late-onset 11.1 COMT DRD3 DRD4 SLC6A3 SLC6A4
37 vallecula cancer 11.1 COMT SLC6A4 TPH2
38 alcoholic liver cirrhosis 11.1 DRD3 DRD4 SLC6A4
39 cerebral creatine deficiency syndrome 1 11.0
40 impulse control disorder 11.0
41 chromosome 15q11.2 deletion syndrome 11.0
42 chromosome 16p11.2 deletion syndrome, 220-kb 11.0
43 legius syndrome 11.0
44 epilepsy, focal, with speech disorder and with or without mental retardation 11.0
45 intellectual developmental disorder with gastrointestinal difficulties and high pain threshold 11.0
46 thyroid hormone resistance 11.0
47 chromosome 1q21.1 deletion syndrome 11.0
48 sexual disorder 11.0 COMT DRD3 DRD4 MECP2 SLC6A3 SLC6A4
49 intracranial cavernous angioma 11.0 SLC6A3 SLC6A4
50 placenta disease 11.0 DRD3 DRD4

Graphical network of the top 20 diseases related to Attention Deficit-Hyperactivity Disorder:



Diseases related to Attention Deficit-Hyperactivity Disorder

Symptoms & Phenotypes for Attention Deficit-Hyperactivity Disorder

Symptoms via clinical synopsis from OMIM:

54

Neuro:
hyperactivity

Misc:
male:female ratio 8:1


Clinical features from OMIM:

143465

Human phenotypes related to Attention Deficit-Hyperactivity Disorder:

32
id Description HPO Frequency HPO Source Accession
1 hyperactivity 32 HP:0000752
2 attention deficit hyperactivity disorder 32 HP:0007018

UMLS symptoms related to Attention Deficit-Hyperactivity Disorder:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Attention Deficit-Hyperactivity Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 ADRA2A COMT DOCK3 DRD3 DRD4 DRD5
2 cardiovascular system MP:0005385 9.61 ADRA2A COMT DRD3 DRD5 GNB5 MECP2
3 nervous system MP:0003631 9.4 SLC6A3 SLC6A4 TPH2 ADRA2A COMT DOCK3

Drugs & Therapeutics for Attention Deficit-Hyperactivity Disorder

Drugs for Attention Deficit-Hyperactivity Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 325)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 113-45-1 4158
3
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
4
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2 29110-47-2 3519
5
Clonidine Approved Phase 4,Phase 3,Phase 2 4205-90-7 2803
6
Dextroamphetamine Approved, Illicit Phase 4,Phase 3,Phase 1,Phase 2 51-64-9 5826
7
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
8
Valproic Acid Approved, Investigational Phase 4,Phase 3 99-66-1 3121
9
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
10
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
11
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
12
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
13
Sertraline Approved Phase 4 79617-96-2 68617
14
Topiramate Approved Phase 4 97240-79-4 5284627
15
Ziprasidone Approved Phase 4,Phase 2 146939-27-7 60854
16 Piracetam Approved Phase 4 7491-74-9
17
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
18
Methamphetamine Approved, Illicit Phase 4,Phase 2 537-46-2 10836
19
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
20
Amphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 300-62-9 5826 3007
21
Galantamine Approved Phase 4 357-70-0 9651
22
Bupropion Approved Phase 4,Phase 3,Phase 2 34841-39-9, 34911-55-2 444
23
Nicotine Approved Phase 4,Phase 3,Phase 1 54-11-5 942 89594
24
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
25
Milnacipran Approved Phase 4 92623-85-3 65833
26
Cyproheptadine Approved Phase 4 129-03-3 2913
27
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1 75614-87-8, 51-45-6 774
28
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 112111-43-0
29
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 68693-11-8 4236
30
Carbon monoxide Approved Phase 4 630-08-0 281
31
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
32
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
33
Oxcarbazepine Approved Phase 4 28721-07-5 34312
34
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
35
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 73-31-4 896
36 tannic acid Approved, Nutraceutical Phase 4,Phase 3
37 Tocopherol Approved, Nutraceutical Phase 4,Phase 2,Phase 3
38
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 1406-16-2
39
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-02-9 14985
40
Glutamic Acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 56-86-0 33032
41 Etiracetam Investigational Phase 4 33996-58-6
42 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1
43 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1
44 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
50 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1079)

id Name Status NCT ID Phase Drugs
1 Comparing Treatment With Melatonin to Treatment With Stimulants (Methylphenidate) in Children With Attention Deficit Hyperactivity Disorder and Sleep Difficulties Unknown status NCT01393574 Phase 4 Melatonin;Methylphenidate
2 Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children Unknown status NCT00754208 Phase 4 methylphenidate
3 Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT01339286 Phase 4 atomoxetine
4 Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD) Unknown status NCT00862108 Phase 4 Methylphenidate
5 Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD Unknown status NCT02074228 Phase 4 Methylphenidate (Concerta)
6 Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents Unknown status NCT00536419 Phase 4 Methylphenidate
7 Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD Unknown status NCT01709695 Phase 4 Guanfacine Hydrochloride XR;Placebo
8 Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children Unknown status NCT02545634 Phase 4
9 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
10 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
11 Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder Unknown status NCT01130467 Phase 4 methylphenidate;Atomoxetine
12 Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
13 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Unknown status NCT02048241 Phase 4 Intuniv
14 Juvenile Bipolar Disorder Outpatient Program Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
15 Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents Unknown status NCT00252278 Phase 4 atomoxetine
16 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
17 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
18 Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation Unknown status NCT01924429 Phase 4 Lisdexamphetamine
19 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4 METHYLPHENIDATE
20 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4 levetiracetam
21 Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder Completed NCT01439126 Phase 4 clonidine hydrochloride;Placebo
22 Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children Completed NCT01065259 Phase 4 OROS MPH;Atomoxetine
23 A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants Completed NCT01933880 Phase 4 Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)
24 Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00783835 Phase 4 Long-Acting Methylphenidate
25 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4 Atomoxetine Hydrochloride;Placebo
26 A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder Completed NCT00518232 Phase 4 OROS-methylphenidate
27 Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder Completed NCT00866996 Phase 4 Methylphenidate extended-release; Atomoxetine
28 An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder. Completed NCT01873729 Phase 4 Naltrexone
29 Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD) Completed NCT00842127 Phase 4 OROS-methylphenidate (Concerta)
30 Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults Completed NCT00753012 Phase 4 Lisdexamfetamine
31 Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD) Completed NCT00760747 Phase 4 Atomoxetine
32 Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder Completed NCT01831622 Phase 4 Ritalin;Placebo
33 An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01012622 Phase 4 Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
34 Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00937040 Phase 4 OROS MPH;Placebo;OROS MPH Tablets;Placebo Tablets
35 A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Completed NCT00471354 Phase 4 Atomoxetine
36 Autonomic Correlates of Impulsivity for Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00856063 Phase 4 atomoxetine (or placebo)
37 Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01238822 Phase 4 Methylphenidate;placebo;Methylphenidate;Methylphenidate
38 Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder Completed NCT00429273 Phase 4 Guanfacine;Methylphenidate (MPH)
39 Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01069523 Phase 4 Guanfacine Extended Release;Placebo
40 An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT01060150 Phase 4 OROS Methylphenidate HCl
41 A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors Completed NCT01624649 Phase 4 Methylphenidate hydrochloride;Atomoxetine
42 Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00546910 Phase 4 Atomoxetine;Placebo
43 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
44 Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder) Completed NCT00221962 Phase 4 Aripiprazole
45 Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine Completed NCT01146002 Phase 4 Guanfacine (sustained release)
46 Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD Completed NCT00585910 Phase 4 Atomoxetine and OROS Methylphenidate
47 A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder Completed NCT00181571 Phase 4 methylphenidate HCl (Concerta);Placebo
48 Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory Completed NCT00530257 Phase 4 Placebo;OROS-methylphenidate
49 Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS) Completed NCT00181766 Phase 4 Strattera (atomoxetine)
50 Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials Completed NCT01063153 Phase 4 Osmotic Release Methylphenidate

Search NIH Clinical Center for Attention Deficit-Hyperactivity Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: attention deficit disorder with hyperactivity

Genetic Tests for Attention Deficit-Hyperactivity Disorder

Genetic tests related to Attention Deficit-Hyperactivity Disorder:

id Genetic test Affiliating Genes
1 Attention Deficit Hyperactivity Disorder 29

Anatomical Context for Attention Deficit-Hyperactivity Disorder

MalaCards organs/tissues related to Attention Deficit-Hyperactivity Disorder:

39
Brain, Testes, Thyroid, Eye, Liver, Breast, Heart

Publications for Attention Deficit-Hyperactivity Disorder

Articles related to Attention Deficit-Hyperactivity Disorder:

(show top 50) (show all 1427)
id Title Authors Year
1
Are patients with bipolar disorder and comorbid attention-deficit hyperactivity disorder more neurocognitively impaired? ( 28941032 )
2017
2
Sleep problems in children with attention-deficit hyperactivity disorder: associations with parenting style and sleep hygiene. ( 28509968 )
2017
3
Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults. ( 28495551 )
2017
4
Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. ( 28073796 )
2017
5
Trichotillomania in Attention-Deficit/Hyperactivity Disorder Under Methylphenidate Treatment. ( 28492426 )
2017
6
Exploring the Validity of Proposed Transgenic Animal Models of Attention-Deficit Hyperactivity Disorder (ADHD). ( 28534274 )
2017
7
Unmet Medication Coverage Needs among Adults with Attention Deficit/Hyperactivity Disorder (ADHD). ( 28936005 )
2017
8
Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults - Authors' reply. ( 28495548 )
2017
9
Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults. ( 28495546 )
2017
10
Differential therapeutic effects of atomoxetine and methylphenidate in childhood attention deficit/hyperactivity disorder as measured by near-infrared spectroscopy. ( 28507595 )
2017
11
Emerging role of miRNA in attention deficit hyperactivity disorder: a systematic review. ( 28493018 )
2017
12
Attention-deficit/hyperactivity disorder and suicide: A systematic review. ( 28401048 )
2017
13
The relationship of social anxiety disorder symptoms with probable attention deficit hyperactivity disorder in Turkish university students; impact of negative affect and personality traits of neuroticism and extraversion. ( 28460287 )
2017
14
Critical exploration of co-occurring Attention-Deficit/Hyperactivity Disorder, mood disorder and Substance Use Disorder. ( 28686107 )
2017
15
The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder. ( 28398816 )
2017
16
Structural Brain Abnormalities of Attention-Deficit/Hyperactivity Disorder With Oppositional Defiant Disorder. ( 28911901 )
2017
17
Therapy access among children with autism spectrum disorder, cerebral palsy, and attention-deficit-hyperactivity disorder: a population-based study. ( 28940224 )
2017
18
Cognitive profiles of adults with high-functioning autism spectrum disorder and those with attention-deficit/hyperactivity disorder based on the WAIS-III. ( 28064024 )
2017
19
Pharmacokinetics of a New Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder. ( 28933918 )
2017
20
The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder. ( 28368900 )
2017
21
Handedness and Attention Deficit/Hyperactivity Disorder Symptoms in College Students. ( 28508302 )
2017
22
Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism. ( 28072412 )
2017
23
The Impact of Methylphenidate on Motor Performance in Children with both Attention Deficit Hyperactivity Disorder and Developmental Coordination Disorder: A Randomized Double-Blind Crossover Clinical Trial. ( 28761201 )
2017
24
Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults. ( 28495550 )
2017
25
Diagnostic utility of brain activity flow patterns analysis in attention deficit hyperactivity disorder. ( 28065167 )
2017
26
Iron Status in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. ( 28046016 )
2017
27
Attention-Deficit Hyperactivity Disorder (ADHD) Symptoms in Children Adopted from Poland and their Atypical Association Patterns: a Bayesian Approach. ( 28523385 )
2017
28
Auditory Processing Assessment in Children with Attention Deficit Hyperactivity Disorder: An Open Study Examining Methylphenidate Effects. ( 28050211 )
2017
29
Neuropsychological performance measures as intermediate phenotypes for attention-deficit/hyperactivity disorder: A multiple mediation analysis. ( 27049476 )
2017
30
Insomnia in adult attention-deficit/hyperactivity disorder: A comparison with borderline personality disorder population in a clinical setting and control participants. ( 28501733 )
2017
31
Attention-Deficit/Hyperactivity Disorder in Looked-After Children: a Systematic Review of the Literature. ( 28932648 )
2017
32
Vineland-II adaptive behavior profile of children with attention-deficit/hyperactivity disorder or specific learning disorders. ( 28056381 )
2017
33
Use of glucocorticoids during pregnancy and risk of attention-deficit/hyperactivity disorder in offspring: a nationwide Danish cohort study. ( 28947451 )
2017
34
Revisiting the co-existence of Attention-Deficit/Hyperactivity Disorder and Chronic Tic Disorder in childhood-The case of colour discrimination, sustained attention and interference control. ( 28594866 )
2017
35
Anxiety and Depression among College Students with Attention-Deficit/Hyperactivity Disorder (ADHD): Cross-Informant, Sex, and Subtype Differences. ( 28937938 )
2017
36
Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder. ( 28225747 )
2017
37
Attention-deficit/hyperactivity disorder (ADHD): from randomised controlled trials to evidence-based clinical services. ( 28065196 )
2017
38
A Methylome-Wide Association Study of Trajectories of Oppositional Defiant Behaviors and Biological Overlap With Attention Deficit Hyperactivity Disorder. ( 28929496 )
2017
39
Adult attention deficit hyperactivity disorder and driving - risk, medication and fitness to drive. ( 28952682 )
2017
40
Evaluation of Knowledge and Attitude of Parents of Attention Deficit/Hyperactivity Disorder Children towards Attention Deficit/Hyperactivity Disorder in Clinical Samples. ( 28496501 )
2017
41
Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs. ( 28473157 )
2017
42
Differential neuropsychological functioning between adolescents with attention-deficit/hyperactivity disorder with and without conduct disorder. ( 28292624 )
2017
43
Distracted Driving With Attention-Deficit/Hyperactivity Disorder. ( 28492867 )
2017
44
Age-dependent effects of acute methylphenidate on amygdala reactivity in stimulant treatment-naive patients with Attention Deficit/Hyperactivity Disorder. ( 28938219 )
2017
45
Persisting Psychosocial Impairments in Adults Being Treated with Medication for Attention Deficit/Hyperactivity Disorder. ( 28936004 )
2017
46
Shared and disorder-specific task-positive and default mode network dysfunctions during sustained attention in paediatric Attention-Deficit/Hyperactivity Disorder and obsessive/compulsive disorder. ( 28529874 )
2017
47
Cognitively and physically demanding exergaming to improve executive functions of children with attention deficit hyperactivity disorder: a randomised clinical trial. ( 28068954 )
2017
48
A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( 28806385 )
2017
49
Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials. ( 28052720 )
2017
50
Investigation of Attention Deficit Hyperactivity Disorder (ADHD) sub-types in Children via EEG Frequency Domain analysis. ( 28925800 )
2017

Variations for Attention Deficit-Hyperactivity Disorder

ClinVar genetic disease variations for Attention Deficit-Hyperactivity Disorder:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 VPS13B NM_017890.4(VPS13B): c.1219C> T (p.Gln407Ter) single nucleotide variant Pathogenic/Likely pathogenic rs386834070 GRCh37 Chromosome 8, 100146872: 100146872
2 MECP2 NM_001110792.1(MECP2) indel Pathogenic rs786205019 GRCh38 Chromosome X, 154030644: 154030664
3 C12orf57 NM_138425.3(C12orf57): c.53-2A> G single nucleotide variant Pathogenic rs1114167293 GRCh37 Chromosome 12, 7053637: 7053637
4 GNB5 NM_006578.3(GNB5): c.242C> T (p.Ser81Leu) single nucleotide variant Pathogenic/Likely pathogenic rs761399728 GRCh37 Chromosome 15, 52446144: 52446144
5 HIVEP1 NM_002114.3(HIVEP1): c.4089G> C (p.Met1363Ile) single nucleotide variant Pathogenic rs776300630 GRCh37 Chromosome 6, 12124117: 12124117
6 CDK20 NM_001039803.2(CDK20): c.564G> A (p.Trp188Ter) single nucleotide variant Pathogenic rs1057519438 GRCh37 Chromosome 9, 90584834: 90584834

Copy number variations for Attention Deficit-Hyperactivity Disorder from CNVD:

7 (show top 50) (show all 84)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 34465 1 56053497 56064495 Deletion USP24 Attention deficit hyperactivity disorder
2 34466 1 56053497 56064495 Deletion USP24e Attention deficit hyperactivity disorder
3 36125 1 72317292 72328395 Duplication NEGR1 Attention deficit hyperactivity disorder
4 49516 11 107520009 107885084 Duplication C11orf65 Attention deficit hyperactivity disorder
5 49517 11 107520009 107885084 Duplication EXPH5 Attention deficit hyperactivity disorder
6 49518 11 107520009 107885084 Duplication KDELC2 Attention deficit hyperactivity disorder
7 60337 11 85300000 92300000 Deletion GRM5 Attention deficit hyperactivity disorder
8 60583 11 88269449 88351661 Deletion GRM5 Attention deficit hyperactivity disorder
9 60585 11 88269449 88351661 Het ACAT1 Attention deficit hyperactivity disorder
10 60586 11 88269449 88351661 Het ATM Attention deficit hyperactivity disorder
11 60587 11 88269449 88351661 Het GRM5 Attention deficit hyperactivity disorder
12 60588 11 88269449 88351661 Het NPAT Attention deficit hyperactivity disorder
13 63163 12 115300000 116700000 Duplicated NOS1 Attention deficit hyperactivity disorder
14 69603 12 55902280 55923860 Deletion NDUFA4L2 Attention deficit hyperactivity disorder
15 69604 12 55902280 55923860 Deletion NXPH4 Attention deficit hyperactivity disorder
16 69605 12 55902280 55923860 Deletion SHMT2 Attention deficit hyperactivity disorder
17 69606 12 55902280 55923860 Deletion STAC3 Attention deficit hyperactivity disorder
18 75846 13 24844208 25493420 Duplication or delet ion ATP8A2 Attention deficit hyperactivity disorder
19 76965 13 38815028 39075356 Duplication or delet ion LHFP Attention deficit hyperactivity disorder
20 78033 13 48967801 49001118 Duplication or delet ion PHF11 Attention deficit hyperactivity disorder
21 78043 13 49004082 49057720 Duplication or delet ion RCBTB1 Attention deficit hyperactivity disorder
22 79472 13 72254230 72488592 Duplication or delet ion PIBF1 Attention deficit hyperactivity disorder
23 91412 15 30110017 30248527 Deletion CHRNA7 Attention deficit hyperactivity disorder
24 99563 16 27600000 34400000 Deleted ERK1 Attention deficit hyperactivity disorder
25 99685 16 28100000 34600000 Deletion CORO1A Attention deficit hyperactivity disorder
26 101713 16 45500000 51200000 Duplicated ZNF423 Attention deficit hyperactivity disorder
27 103489 16 6072599 6783832 Duplication A2BP1 Attention deficit hyperactivity disorder
28 106366 16 87694595 87778383 Deletion CDH15 Attention deficit hyperactivity disorder
29 109330 17 25613604 26191779 Duplication BLMH Attention deficit hyperactivity disorder
30 117083 17 71112486 71120734 Deletion Attention deficit hyperactivity disorder
31 122044 18 52000000 54400000 Duplicated NEDD4L Attention deficit hyperactivity disorder
32 123018 18 65358832 65367619 Deletion DOK6 Attention deficit hyperactivity disorder
33 125924 19 15992679 15997923 Deletion LOC126536 Attention deficit hyperactivity disorder
34 127980 19 38427720 38444834 Deletion SLC7A10 Attention deficit hyperactivity disorder
35 127981 19 38427720 38444834 Deletion SLC7A10e Attention deficit hyperactivity disorder
36 132645 19 59423491 59428132 Duplication LILRB3 Attention deficit hyperactivity disorder
37 132646 19 59423491 59428132 Duplication LIR-3 Attention deficit hyperactivity disorder
38 136696 2 132200000 134800000 Deleted NAP5 Attention deficit hyperactivity disorder
39 139372 2 1792886 2335045 Duplication or delet ion MYT1L Attention deficit hyperactivity disorder
40 146272 2 47600000 52700000 Deleted NRXN1 Attention deficit hyperactivity disorder
41 146517 2 50145643 51259674 Duplication or delet ion NRXN1 Attention deficit hyperactivity disorder
42 146826 2 55088956 55239201 Duplication RTN4 Attention deficit hyperactivity disorder
43 148301 2 75400000 83700000 Deleted CTNNA2 Attention deficit hyperactivity disorder
44 148598 2 81419297 81446082 Duplication CTNNA2 Attention deficit hyperactivity disorder
45 148599 2 81419297 81446082 Duplication CTNNA2e Attention deficit hyperactivity disorder
46 154924 20 5000000 9000000 Deleted BMP2 Attention deficit hyperactivity disorder
47 164095 22 34870070 34916870 Het APOL3 Attention deficit hyperactivity disorder
48 164096 22 34870070 34916870 Het APOL4 Attention deficit hyperactivity disorder
49 164674 22 38384374 38403731 Deletion CACNA1I Attention deficit hyperactivity disorder
50 166998 3 111722434 117006477 Deletion Attention deficit hyperactivity disorder

Expression for Attention Deficit-Hyperactivity Disorder

Search GEO for disease gene expression data for Attention Deficit-Hyperactivity Disorder.

Pathways for Attention Deficit-Hyperactivity Disorder

GO Terms for Attention Deficit-Hyperactivity Disorder

Cellular components related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.26 SLC6A2 SLC6A3 SLC6A4 TPH2
2 integral component of plasma membrane GO:0005887 9.17 ADRA2A DRD3 DRD4 DRD5 SLC6A2 SLC6A3

Biological processes related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

(show all 27)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.89 COMT DRD3 SLC6A2 SLC6A3 SLC6A4
2 cellular calcium ion homeostasis GO:0006874 9.78 DRD3 DRD4 DRD5
3 neurotransmitter transport GO:0006836 9.69 SLC6A2 SLC6A3 SLC6A4
4 response to cocaine GO:0042220 9.65 DRD3 DRD5 SLC6A3
5 behavioral response to cocaine GO:0048148 9.63 DRD3 DRD4
6 response to pain GO:0048265 9.63 COMT SLC6A2
7 negative regulation of adenylate cyclase activity GO:0007194 9.63 ADRA2A DRD3 DRD4
8 synaptic transmission, dopaminergic GO:0001963 9.62 DRD3 DRD5
9 negative regulation of protein secretion GO:0050709 9.62 DRD3 DRD4
10 learning GO:0007612 9.62 COMT DRD3 DRD5 MECP2
11 negative regulation of cAMP biosynthetic process GO:0030818 9.61 ADRA2A DRD4
12 neurotransmitter biosynthetic process GO:0042136 9.6 SLC6A3 SLC6A4
13 negative regulation of voltage-gated calcium channel activity GO:1901386 9.59 DRD4 GNB5
14 ammonium transmembrane transport GO:0072488 9.58 SLC6A3 SLC6A4
15 locomotory behavior GO:0007626 9.58 DRD3 SLC6A3
16 response to amphetamine GO:0001975 9.58 DRD3 DRD4 DRD5
17 prepulse inhibition GO:0060134 9.57 DRD3 SLC6A3
18 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.56 DRD3 DRD4
19 social behavior GO:0035176 9.56 DRD3 DRD4 MECP2 SLC6A4
20 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.55 DRD3 DRD5
21 regulation of dopamine metabolic process GO:0042053 9.54 DRD4 SLC6A3
22 dopamine metabolic process GO:0042417 9.54 COMT DRD3 DRD4
23 dopamine catabolic process GO:0042420 9.52 COMT SLC6A3
24 response to histamine GO:0034776 9.43 DRD3 DRD4
25 monoamine transport GO:0015844 9.33 SLC6A2 SLC6A3 SLC6A4
26 dopamine uptake involved in synaptic transmission GO:0051583 9.13 SLC6A2 SLC6A3 SLC6A4
27 dopamine receptor signaling pathway GO:0007212 8.8 DRD3 DRD4 GNB5

Molecular functions related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.72 ADRA2A DRD3 DRD4 DRD5 GNB5
2 symporter activity GO:0015293 9.63 SLC6A2 SLC6A3 SLC6A4
3 drug binding GO:0008144 9.58 DRD3 DRD4 SLC6A3
4 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A3 SLC6A4
5 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A2 SLC6A3 SLC6A4
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD3 DRD4
7 dopamine neurotransmitter receptor activity GO:0004952 9.33 DRD3 DRD4 DRD5
8 dopamine:sodium symporter activity GO:0005330 9.13 SLC6A2 SLC6A3 SLC6A4
9 dopamine binding GO:0035240 8.92 DRD3 DRD4 DRD5 SLC6A3

Sources for Attention Deficit-Hyperactivity Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....